Has results × Lung Neoplasms × Erlotinib Hydrochloride × Clear all A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
92 enrolled 14 charts
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Phase 1/2 Completed
24 enrolled 8 charts
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Phase 2 Terminated
8 enrolled 6 charts
BELIEF
Phase 2 Completed
109 enrolled 20 charts
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
334 enrolled 14 charts
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Phase 2 Completed
44 enrolled 16 charts
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2 Completed
222 enrolled 23 charts
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Phase 2 Completed
201 enrolled 12 charts
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1 Completed
17 enrolled 12 charts
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Phase 3 Completed
636 enrolled 14 charts
TARLAL
Phase 2 Completed
15 enrolled 6 charts
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
24 enrolled 12 charts
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
32 enrolled 13 charts
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Phase 2 Completed
84 enrolled 15 charts
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
Phase 2 Completed
89 enrolled 11 charts
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
59 enrolled 13 charts
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
37 enrolled 9 charts
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
68 enrolled 11 charts
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
86 enrolled 9 charts
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
81 enrolled 14 charts
HER3-Lung
Phase 3 Terminated
145 enrolled 20 charts
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Phase 2 Completed
9 enrolled 6 charts
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Phase 2 Completed
38 enrolled 13 charts
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
Phase 2 Completed
59 enrolled 7 charts
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
46 enrolled 15 charts
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
116 enrolled 11 charts
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Phase 2 Completed
89 enrolled 28 charts
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
Phase 1/2 Completed
64 enrolled 11 charts
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
Phase 2 Completed
147 enrolled 16 charts
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Phase 2 Completed
137 enrolled 11 charts
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1/2 Completed
162 enrolled 11 charts
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
53 enrolled 10 charts
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
Phase 2 Terminated
5 enrolled 4 charts
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
Phase 2 Completed
25 enrolled 12 charts
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Phase 2 Completed
202 enrolled 8 charts
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Phase 2 Terminated
6 enrolled 6 charts
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Phase 2 Terminated
2 enrolled 3 charts
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1 Completed
27 enrolled 22 charts
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
46 enrolled 12 charts
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Phase 2 Completed
188 enrolled 14 charts
RADIANT
Phase 3 Completed
1,252 enrolled 24 charts
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Phase 2 Terminated
45 enrolled 4 charts
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Phase 1/2 Completed
21 enrolled 8 charts
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Phase 2 Completed
123 enrolled 9 charts
A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
40 enrolled 6 charts
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
Phase 2 Completed
143 enrolled 12 charts